Ex-vivo / in-vitro studies on immune-activators and blockers in hidradenitis suppurativa

Withdrawn

• Conditions: De proefpersonen fungeren als de controle groep van patienten met de huidziekte hidradenitis suppurativa.; acne inversa; verneuil's disease

• Registration Number: NL-OMON49375
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

Inclusion criteria cases * HS patients
- Participating in HiScreen Biobank
- Informed consent available for blood samples

Inclusion criteria controls
- Adult (> 18 years old) patients not suffering from HS.
- Competent and willing to provide informed consent.

Exclusion Criteria

Exclusion criteria HS patients
- <18 years of age
- use of systemic or local antibiotics in the past 2 weeks
- use of any other medication potentially affecting the cytokine/antimicrobial
profiles

-
Exclusion criteria controls
- <18 years of age
- known with hidradenitis suppurativa
- use of systemic and local antibiotics in the past 2 weeks
- use of any other medication potentially affecting the cytokine/antimicrobial
profiles
- pregnant women

Exclusion criteria controls
- <18 years of age
- known with hidradenitis suppurativa
- use of systemic and or local antibiotics in the past 2 weeks
- use of any other medication potentially affecting the cytokine/antimicrobial
profiles
- no relatives with HS
- pregnant women

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study parameter is the difference of immune response to above<br /><br>mentioned HS triggering factors, for example the cytokine/antimicrobial profile<br /><br>after microbial exposure in HS patients compared to healthy controls. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>N.A. </p><br>